Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
Kai Liang TehLena DasYun Xin BookSook Fun HohXiaocong GaoThaschawee ArkachaisriPublished in: Clinical rheumatology (2024)
Duration of weaning aTNF may not minimize flare rate or delay time to flare after stopping treatment in JIA patients. Recapture rates for inactive disease at 6 months remained high for patients who flared after weaning or discontinuing medication.
Keyphrases
- juvenile idiopathic arthritis
- mechanical ventilation
- end stage renal disease
- disease activity
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- healthcare
- prognostic factors
- peritoneal dialysis
- intensive care unit
- acute respiratory distress syndrome
- adverse drug
- patient reported
- smoking cessation
- drug induced